AEF-0117 is under clinical development by Aelis Farma and currently in Phase II for Substance (Drug) Abuse. According to GlobalData, Phase II drugs for Substance (Drug) Abuse have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AEF-0117’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AEF-0117 overview

AEF-0117 is under development for the treatment of cannabis abuse. The drug candidate is administered orally. The drug candidate is a new molecular entity. It is a C3,17-NMPD (non metabolized pregnenolone derivative). It acts by targeting cannabinoid receptor 1.

Aelis Farma overview

Aelis Farma is a biotech company that conducts research and development on signaling-specific drugs. The company develops cannabinoid receptor type 1 signaling-specific inhibitors. It’s signaling-specific therapeutics target the G-protein-coupled receptors. Aelis Farma’s CB1 receptors find application in treating various diseases such as psychosis, mental retardation, metabolic disorders and skin diseases. Aelis Farma also develops a new pharmacological class signaling specific inhibitors for the stimulation of MAP-kinase pathway to reduce most of THC behavioral effects. The company’s product modulates the signaling pathway related with the disease and offers pharmaceutical compounds with required therapeutic efficacy and fewer side effects. It operates through its research centers and universities to develop new signaling-biased drugs. The company caters to healthcare sector. Aelis Farma is headquartered in Bordeaux, France.

For a complete picture of AEF-0117’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.